From cancer immunotherapy and antibiotics to GMO crops and pandemic surveillance, gain of function is a cornerstone of basic research.
Academic rigor, journalistic flair
Articles on CAR-T
Displaying all articles
Immunotherapy has the potential to eliminate tumors, but works best for select patients. Engineering T cells to bypass cancer’s defenses could help expand treatment eligibility to more patients.
German doctors have reported success in treating patients with severe lupus, using cell treatments like those used for some forms of blood cancer.
CAR-T is a powerful new immunotherapy for treating leukaemia. We need to build on it to attack other, harder-to-treat cancers.
Top contributors
-
Head, School of Clincial Sciences at Monash Health, Monash University
-
Associate Professor of Microbiology and Immunology at Emory University and Adjunct Professor Microbiology and Molecular Genetics, University of Pittsburgh
-
Senior Lecturer in Haematology, Immunolgy, Genetics and Evolution, University of Central Lancashire
-
Assistant Professor of Medicine, University of California, San Francisco
-
Associate Professor of Microbiology and Immunology, Emory University
